Mircera approved for monthly dosing in ESA-naive patients

The renal anaemia treatment Mircera (methoxypolyethyleneglycol-epoetin beta) can now be administered once monthly in patients who are not on dialysis and are not currently receiving an erythropoiesis-stimulating agent. At this dosing interval, the recommended dose is 1.2 microgram/kg by subcutaneous injection.

The long-acting erythropoietin receptor activator was previously licensed only for fortnightly dosing in this population.

View Mircera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Find alternatives to out-of-stock products with MIMS tables

Find alternatives to out-of-stock products with MIMS tables

With a recent increase in the number of drugs in short...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

New buprenorphine injection allows weekly or monthly treatment of opioid dependence

New buprenorphine injection allows weekly or monthly treatment of opioid dependence

Buvidal (buprenorphine) is licensed for the treatment...

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.